Alterity Therapeutics to Participate in Two Upcoming Investor Conferences
MELBOURNE, Australia and SAN FRANCISCO, Nov. 22, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced that David Stamler, M.D., Chief Executive Officer will participate in two upcoming virtual investor events: MST Financial Lifesciences &...
CARsgen Receives CTA Authorization from Health Canada for CLDN18.2-targeted CAR T-cell Product CT041
SHANGHAI, Nov. 22, 2021 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company mainly focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, today announced that the Company has received a No Objection Letter from Health Canada in response to the Clinical Trial Application...
Baidu Enters Into License Agreement With Sanofi to Enable Next-Generation mRNA Therapeutics and Vaccines
BEIJING, Nov. 22, 2021 /PRNewswire/ -- Baidu, Inc. (NASDAQ:BIDU and HKEX:9888), a leading AI company with strong Internet foundation, and Sanofi, a leading biopharmaceutical company focused on human health, have entered into an agreement to integrate Baidu's messenger ribonucleic acid (mRNA) design optimization platform, LinearDesign, into Sanofi's product design pipeline. Under the agreement, Sanofi will leverage the LinearDesign...
Resource for journalists around the world on COVID-19 vaccines
covidvaccinehub.org (https://covidvaccinehub.org/) If you're a fact checker or a journalist, we're here to help you find the information and experts you need for your story. SYDNEY, Nov. 22, 2021 /PRNewswire/ -- The COVID-19 Vaccine Media Hub (https://covidvaccinehub.org/) is a dedicated global resource for journalists and fact checkers wanting access to evidence-based information on COVID-19 vaccines with material available in...
Innovent Releases the ORIENT-31 Phase 3 Study First Interim Analysis Results of Sintilimab plus BYVASDA (bevacizumab biosimilar injection) and Chemotherapy in Patients with EGFR-mutated Nonsquamous Non-small Cell Lung Cancer...
SAN FRANCISCO and SUZHOU, China, Nov. 22, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, today announced first interim analysis results of the randomized, double-blinded, multi-center Phase 3 ORIENT-31 study conducted in China evaluating sintilimab and...
Innovent Announces Inclusion of the Company’s Stock (01801.HK) in the Hang Seng China Enterprises Index
SAN FRANCISCO and SUZHOU, China, Nov. 22, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, announces the Company's stock is included in the Hang Seng China Enterprises Index (HSCEI) according to the Hang Seng Indexes Company's...
CStone Pharmaceuticals and Jiangsu Hengrui Pharmaceuticals announce strategic partnership and exclusive licensing agreement on anti-CTLA-4 monoclonal antibody CS1002 in Greater China
SUZHOU, China, Nov. 21, 2021 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, and Jiangsu Hengrui Pharmaceuticals ("Hengrui", SHSE: 600276) today announced a strategic partnership and exclusive licensing agreement on anti-CTLA-4 mAb CS1002 in the Greater China region. This strategic partnership marks another milestone in...
Nestle Health Science Partners with Healint to Initiate a Fully Virtual Study on Ketogenic Treatment for Migraines
SINGAPORE, Nov. 21, 2021 /PRNewswire/ -- Nestlé Health Science (NHSc) has initiated a study looking into the effectiveness of a ketogenic nutritional supplement in reducing migraine attacks. The fully virtual study, taking place in Quebec, Canada, is investigating the effectiveness of a ketogenic nutritional supplement developed by Nestlé in reducing the number,...
Successful 2020 Tang Prize Award Ceremony Highlights Laureates’ Achievements and Influence
TAIPEI, Nov. 20, 2021 /PRNewswire/ -- The 2020 Tang Prize Award Ceremony took place virtually at 2p.m. (GMT+8) on November 20. Eight 2020 recipients of the prize from seven countries, including the U.S., the U.K., Japan, Singapore, Bangladesh, Colombia, and Lebanon, attended this heartwarming event remotely, where they were greeted with congratulations and applause from audiences all over the...
US FDA Grants Breakthrough Designation for Early-Stage Breast Cancer Detection Blood Test Developed by Datar Cancer Genetics
LONDON, Nov. 20, 2021 /PRNewswire/ -- Datar Cancer Genetics, a leading cancer research company focussed on early detection of cancers today announced that the US Food and Drug Administration (FDA) has granted 'Breakthrough Device Designation' for its blood test to detect early-stage Breast Cancer. The Breakthrough Designation is granted by the US...
